NVO ▼ -5.2% - Novo Nordisk A/S $NVO SAYS CAGRISEMA MET WEIGHT-LOSS SUPERIORITY IN PHASE 3 REDEFINE 9 TYPE 2 DIABETES AND OVERWEIGHT/OBESITY TRIAL Novo Nordisk shares fell 5.2% despite the company announcing that its drug Cagrisema met the primary endpoint of weight-loss superiority in the Phase 3 REDEFINE 9 trial for type 2 diabetes and overweight/obesity. The positive trial result suggests the market may have had higher expectations, or investors reacted to other factors not detailed in the headline. 21-SEP-2026 06:30 AM ET